Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br As the population continues to age and

    2020-08-30


    As the 2-Deoxy-D-glucose continues to age and longevity from cardiovascu-lar disease continues to improve, better and more pragmatic tools that can be integrated into busy clinical practices are needed to optimally se-lect older patients with cancer for curative therapy. With appropriate use of chemotherapy, as well as ongoing management of co-morbid conditions, outcomes in older patients with colon cancer can be signifi-cantly improved.
    Authorship Contributions
    Contribution: Name(s) of author(s)
    Study concepts: Raycraft, Mariano, Cheung, Speers. Ko…
    Study design: Raycraft. Cheung, Ko, Speers. Yin, Mariano
    Data acquisition: Raycraft, Speers, Yin, Mariano
    Quality control of data and algorithms: Speers, Yin, Raycraft
    Data analysis and interpretation: Raycraft. Cheung, Ko, Speers. Yin, Mariano
    Statistical analysis: Yin, Speers
    Manuscript preparation: Raycraft. Cheung, Ko, Speers, Yin, Mariano
    Manuscript editing: Raycraft. Cheung, Ko, Speers, Yin, Mariano
    Manuscript review: Raycraft. Cheung, Ko, Speers, Yin, Mariano
    Conflict of Interests
    The authors have no conflicts of interest to declare.
    References
    [1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011 Mar-Apr;61(2):69–90. [2] Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter inter-national study of Oxaliplatin, fluorouracil, and Leucovorin in the adjuvant treatment of Colon Cancer trial. J Clin Oncol 2012 Sep 20;30(27):3353–60.
    [7] Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, et al. Partici-pation of elderly patients in registration trials for oncology drug applications in Japan. Ann Oncol 2010 Oct;21(10):2112–8.
    [10] Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009 Jan;20(1):5–16.
    [17] Schonberg MA, Davis RB, Mccarthy EP, Marcantonio ER. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc 2011 Aug;59(8):1444–51. [18] Kohne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist 2008 Apr;13(4):390–402. [19] Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, et al. Benefits and adverse events in younger versus older patients receiving adjuvant chemother-apy for colon cancer: findings from the adjuvant colon cancer endpoints data set. J Clin Oncol 2012 Jul 1;30(19):2334–9. [20] Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly pa-tients. N Engl J Med 2001 Oct 11;345(15):1091–7.
    [22] Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, et al. Competing causes of death and second primary tumors in patients with locoregionally 
    advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004 Mar 15;10(6):1956–62. [23] Barthelemy P, Heitz D, Mathelin C, Polesi H, Asmane I, Litique V, et al. Adjuvant che-motherapy in elderly patients with early breast cancer. Impact of age and compre-hensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 2011 Aug;79(2):196–204.
    [24] Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of co-morbidity on prostate Cancer-specific mortality: a prospective observational study. J Clin Oncol 2017 Nov 1;35(31):3566–74. [25] Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Cape-citabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon can-cer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012 May;23(5):1190–7.
    [26] Mayer B, Sander S, Paschke S, Henne-Bruns D, Link KH, Kornmann M, et al. Stratified survival analysis after adjuvant chemotherapy of Colon Cancer reveals a benefit for older patients. Anticancer Res 2015 Oct;35(10):5587–93. [27] Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, et al. Comparison of ad-verse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemo-therapy for stage III colon cancer: a population-based analysis. Cancer 2012 Sep 1; 118(17):4309–20.
    [28] Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using surveillance, epidemiology, and end results-Medicare data. J Am Geriatr Soc 2011 Sep;59(9):1717–23.